In 2015, a Zika epidemic in Brazil began spreading throughout the Americas. Zika virus (ZIKV) entered Managua, Nicaragua, in January 2016 and caused an epidemic that peaked in July–September 2016. ZIKV seropositivity was estimated among participants of pediatric (n = 3,740) and household (n = 2,147) cohort studies, including an adult-only subset from the household cohort (n = 1,074), in Managua. Seropositivity was based on a highly sensitive and specific assay, the Zika NS1 blockade-of-binding ELISA, which can be used in dengue-endemic populations. Overall seropositivity for the pediatric (ages 2–14), household (ages 2–80), and adult (ages 15–80) cohorts was 36, 46, and 56%, respectively. Trend, risk factor, and contour mapping analyses demonstrated that ZIKV seroprevalence increased nonlinearly with age and that body surface area was statistically associated with increasing seroprevalence in children. ZIKV seropositivity was higher in females than in males across almost all ages, with adjusted prevalence ratios in children and adults of 1.11 (95% CI: 1.02–1.21) and 1.14 (95% CI: 1.01–1.28), respectively. No household-level risk factors were statistically significant in multivariate analyses. A spatial analysis revealed a 10–15% difference in the risk of ZIKV infections across our 3-km-wide study site, suggesting that ZIKV infection risk varies at small spatial scales. To our knowledge, this is the largest ZIKV seroprevalence study reported in the Americas, and the only one in Central America and in children to date. It reveals a high level of immunity against ZIKV in Managua as a result of the 2016 epidemic, making a second large Zika epidemic unlikely in the near future. Significance Seroprevalence studies are important for determining risk factors for infection and for assessing the susceptible fraction of a population after an epidemic has swept through a population. Here, Zika virus (ZIKV) seroprevalence was estimated among participants of a pediatric cohort, a separate household cohort, and an adult-only subset from the household cohort, in Managua, Nicaragua, after the 2016 Zika epidemic, yielding 36, 46, and 56% seropositivity, respectively. To our knowledge, this is the only ZIKV seroprevalence study reported in Central America and the largest in the Americas and in a pediatric population to date. The explosive 2016 Zika epidemic resulted in a high level of seropositivity to ZIKV, making a second large Zika epidemic in Managua in the near future unlikely.